Takara Bio Inc. (TYO:4974)
1,146.00
-1.00 (-0.09%)
At close: Mar 6, 2026
Takara Bio Revenue
Takara Bio had revenue of 9.60B JPY in the quarter ending December 31, 2025, with 0.78% growth. This brings the company's revenue in the last twelve months to 44.15B, up 2.55% year-over-year. In the fiscal year ending March 31, 2025, Takara Bio had annual revenue of 45.04B with 3.53% growth.
Revenue (ttm)
44.15B
Revenue Growth
+2.55%
P/S Ratio
3.13
Revenue / Employee
24.82M
Employees
1,779
Market Cap
138.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 45.04B | 1.53B | 3.53% |
| Mar 31, 2024 | 43.51B | -34.64B | -44.33% |
| Mar 31, 2023 | 78.14B | 10.44B | 15.43% |
| Mar 31, 2022 | 67.70B | 21.61B | 46.90% |
| Mar 31, 2021 | 46.09B | 11.52B | 33.33% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nxera Pharma | 29.62B |
| GNI Group | 26.84B |
| PeptiDream | 18.52B |
| RaQualia Pharma | 3.98B |
| Japan Tissue Engineering | 2.26B |
| AnGes | 874.00M |
| Cuorips | 356.00M |
| Renascience | 107.00M |